Why Amylyx is pulling ALS drug Relyvrio from US market after study
WASHINGTON (AP) — The maker of a drug for Lou Gehrig’s disease that recently failed in a large study said Thursday it will pull the medicine from the market, acknowledging it didn’t help patients with the deadly neurological condition.
Amylyx Pharmaceuticals announced it will voluntarily halt sales and marketing of the drug in the U.S. and Canada, where new patients will no longer be able to get a prescription.
“While this is a difficult moment for the ALS community, we reached this path forward in partnership with the stakeholders who will be impacted and in line with our steadfast commitment to people living with ALS,” company co-founders said in a statement. Patients already taking the therapy who wish to continue will be able to enroll in a program to receive it for free.
The Food and Drug Administration approved the much-debated drug, Relyvrio, in September 2022, following a years-long advocacy campaign by patients with amyotrophic lateral sclerosis, or ALS.
Related articles
Biden says Brown v. Board of Education ruling was about more than education
WASHINGTON (AP) — The landmark 1954 Supreme Court ruling that desegregated schools was about more th2024-05-21Executor of O.J. Simpson's estate plans to fight payout to the families of Brown and Goldman
LAS VEGAS (AP) — The executor of O.J. Simpson’s estate says he will work to prevent a payout of a $32024-05-21- (Xinhua) 10:35, February 12, 2023NEW YORK, Feb. 11 (Xinhua) -- China's adjustment of its COVID-19 pa2024-05-21
- (Xinhua) 08:06, April 02, 2024BEIJING, April 1 (Xinhua) -- As temperatures warm up across China, spr2024-05-21
- The 'real-life Martha' from Baby Reindeer bombarded Sir Keir Starmer with almost 300 emails, it has2024-05-21
Tennessee Vols wrap up spring practice with Nico Iamaleava finally under center
The Nico Iamaleava era finally has arrived at Tennessee.Sure, the No. 2 quarterback in the 2023 recr2024-05-21
atest comment